These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24384773)

  • 1. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.
    Buijs PR; van Eijck CH; Hofland LJ; Fouchier RA; van den Hoogen BG
    Cancer Gene Ther; 2014 Jan; 21(1):24-30. PubMed ID: 24384773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
    Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
    J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.
    Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
    Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
    Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
    Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.
    Zamarin D; Martínez-Sobrido L; Kelly K; Mansour M; Sheng G; Vigil A; García-Sastre A; Palese P; Fong Y
    Mol Ther; 2009 Apr; 17(4):697-706. PubMed ID: 19209145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity.
    Schwaiger T; Knittler MR; Grund C; Roemer-Oberdoerfer A; Kapp JF; Lerch MM; Mettenleiter TC; Mayerle J; Blohm U
    Int J Cancer; 2017 Dec; 141(12):2505-2516. PubMed ID: 28857157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion.
    García-Romero N; Palacín-Aliana I; Esteban-Rubio S; Madurga R; Rius-Rocabert S; Carrión-Navarro J; Presa J; Cuadrado-Castano S; Sánchez-Gómez P; García-Sastre A; Nistal-Villan E; Ayuso-Sacido A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32516884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
    Huang Z; Liu M; Huang Y
    Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic effect of Newcastle disease virus is attributed to interferon regulation in canine mammary cancer cell lines.
    Santos MR; Xavier PLP; Pires PRL; Rochetti AL; Rosim DF; Scagion GP; de Campos Zuccari DAP; Munir M; Ferreira HL; Fukumasu H
    Vet Comp Oncol; 2021 Sep; 19(3):593-601. PubMed ID: 33871162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
    Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
    Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro.
    Burke S; Shergold A; Elder MJ; Whitworth J; Cheng X; Jin H; Wilkinson RW; Harper J; Carroll DK
    Cancer Immunol Immunother; 2020 Jun; 69(6):1015-1027. PubMed ID: 32088771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
    Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
    BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
    Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D
    Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newcastle disease virus: a promising agent for tumour immunotherapy.
    Zhao L; Liu H
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
    Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
    Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
    Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
    J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Application of Newcastle Disease Virus (NDV): Vaccine Vectors and Tumor Therapy.
    Yang H; Tian J; Zhao J; Zhao Y; Zhang G
    Viruses; 2024 May; 16(6):. PubMed ID: 38932177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.